Fluorine-18 fluorodeoxyglucose (18FDG)-uptake assessment of PDGFRA mutant gastrointestinal stromal tumors (GIST): A retrospective multicenter Italian study.

Authors

Maria Concetta Nigro

Maria Concetta Nigro

Oncology Unit, Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy

Maria Concetta Nigro , Andrea Marchetti , Elena Fumagalli , Ida De Luca , Alexia Francesca Bertuzzi , Maria Susanna Grimaudo , Giovanni Grignani , Lorenzo D'Ambrosio , Alessandra Merlini , Ignazio Carreca , Lorena Incorvaia , Alessandra Dimino , Silvia Gasperoni , Bruno Vincenzi , Maria A. Pantaleo , Margherita Nannini

Organizations

Oncology Unit, Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy, Adult Mesenchymal Tumour & Rare Cancer Medical Oncology Unit, Istituto Nazionale Tumori, Milan, Italy, Adult Mesenchymal Tumour & Rare Cancer Medical Oncology Unit, Istituto Nazionale Tumori, Italy, Milan, Italy, Medical Oncology and Hematology Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center-IRCCS, Rozzano, Milan, Italy, IRCCS Humanitas Research Hospital – Humanitas Cancer Center, Rozzano, Milan, Italy, Italy, Candiolo Cancer Institute, Candiolo, Italy, Department of Medical Oncology, University of Turin, Turin, Italy, Turin, Italy, Sarcoma Unit, Division of Medical Oncology, Candiolo Cancer Institute, FPO, IRCCS, Italy, Candiolo, Italy, Department of Surgical, Oncological, and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy, Medical Oncology, Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy, Palermo, Italy, Department of Oncology and Robotic Surgery, Traslational Oncology Unit, Florence, Italy, Department of Medical Oncology, Fondazione Policlinico Campus Bio-Medico, Rome, Italy

Research Funding

No funding received
None.

Background: D842V PDGFRA mutation identifies a molecular subtype of GIST, primarly resistant to imatinib and characterized by higher indolent behavior and a prominent immune profile. Although functional imaging with 18FDG-PET plays a proven role in GIST, especially in early assessment tumor response, less is known about 18FDG-uptake according to the GIST molecular subtypes. Taking into account of clinical and molecular features of D842V mutant GIST, we assumed that this subset of GIST could also have a different 18FDG-uptake. Therefore, the aim of the present study has been to investigate the degree of FDG uptake of PDGFRA mutant GIST, focusing on D842V ones, in order to better define the role of functional imaging in this rare and peculiar subset of GIST. Methods: Patients with PDGFRA mutant GIST underwent 18FDG-PET were retrospectively included from seven GIST Italian reference centers. Data on maximum standardized uptake (SUVmax) value of primary tumor or metastatic disease were collected. Results: 71 patients have been included: 37 (55.1%) with D842V PDGFRA mutant GIST (group A) and 34 (47.9%) with PDGFRA non-D842V mutant GIST (group B). Additionally, 30 patients with exon 11 KIT mutant GIST have been included, as control (group C). SUVmax values were obtained from primary tumor and metastatic lesions in 55 (54,4%) and 46 (45,6%) patients, respectively. Considering the whole population of 101 patients, the global median SUVmax was 3,7 (IQR 0-9.1), while the median SUVmax for group A, B, and C was 0, 3.6, and 10.4, respectively. The median SUVmax of PDGFRA mutant GIST was significantly lower than the median value of exon 11 KIT mutant GIST (p < 0.001). Notably, median 18FDG-uptake was significantly lower in D842V PDGFRA mutant GIST compared to PDGFRA non-D842V mutant ones (p = 0.021). Conclusions: PDGFRA D842V-mutant GIST present an overall lower 18FDG uptake compared to other GIST subgroups. This feature could be related to their specific molecular background and is consistent with their higher tendency to an indolent behavior. Therefore, the role of functional imaging with 18FDG-PET in this subset of GIST is limited. Finally, the prognostic value of the 18FDG-uptake degree within all PDGFRA mutant GIST will be investigated in the future.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Sarcoma

Track

Sarcoma

Sub Track

Gastrointestinal Stromal Tumors (GIST)

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 11539)

DOI

10.1200/JCO.2023.41.16_suppl.11539

Abstract #

11539

Poster Bd #

473

Abstract Disclosures